Dyrk1 inhibition improves Alzheimer's disease-like pathology-Reference-Cited by-同舟云学术

Dyrk1 inhibition improves Alzheimer's disease-like pathology

Published:2017-08-04 Issue:5 Volume:16 Page:1146-1154
ISSN:1474-9718
Container-title:Aging Cell
language:en
Short-container-title:Aging Cell

Author:

Branca Caterina¹,Shaw Darren M.¹,Belfiore Ramona¹²,Gokhale Vijay³,Shaw Arthur Y.³,Foley Christopher⁴,Smith Breland³,Hulme Christopher³⁴,Dunckley Travis¹,Meechoovet Bessie⁵,Caccamo Antonella¹,Oddo Salvatore¹⁶

Affiliation:

1. The Arizona State University-Banner Neurodegenerative Disease Research Center at the Biodesign Institute; Arizona State University; Tempe AZ 85287 USA

2. Department of Biomedical and Biotechnological Sciences; University of Catania; Catania 95125 Italy

3. Division of Drug Discovery and Development; Department of Pharmacology and Toxicology; College of Pharmacy; The University of Arizona; Tucson AZ 85721 USA

4. Department of Chemistry & Biochemistry; The University of Arizona; Tucson AZ 85721 USA

5. Neurogenomics Division; Translational Genomics Research Institute; Phoenix AZ 85004 USA

6. School of Life Sciences; Arizona State University; Tempe AZ 85287 USA

Funder

Arizona Alzheimer's Consortium

National Institutes of Health

Publisher

Wiley

Subject

Cell Biology,Aging

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/acel.12648/fullpdf

Reference37 articles.

1. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A);Adayev;Arch. Biochem. Biophys.,2011

2. 2015 Alzheimer's disease facts and figures;Alzheimer's;Alzheimer's Dement.,2015

3. High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation;Azorsa;BMC Genom.,2010

4. Administration of a selective beta2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease;Branca;Neurobiol. Aging,2014

5. Cognitive decline typical of frontotemporal lobar degeneration in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43;Caccamo;Am. J. Pathol.,2012

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving significance of kinase inhibitors in the management of Alzheimer's disease;European Journal of Pharmacology;2024-09

2. Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies;Translational Neurodegeneration;2024-08-06

3. Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2024-08

4. Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer’s Disease;Journal of Medicinal Chemistry;2024-07-23

5. Terpenes as Potential Anti-Alzheimer’s Disease Agents;Applied Sciences;2024-05-02